Taking toll: lipid A mimetics as adjuvants and immunomodulators.
about
T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injectionLipid A modification systems in gram-negative bacteriaImmunological Evaluation of Recent MUC1 Glycopeptide Cancer VaccinesMitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems.Lipid A as a Drug Target and Therapeutic MoleculeTargeting Toll-like receptors with small molecule agentsMultiple roles of toll-like receptor 4 in colorectal cancerAdjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvantsStructural biology of membrane-intrinsic beta-barrel enzymes: sentinels of the bacterial outer membraneHigh-throughput profiling of anti-glycan humoral responses to SIV vaccination and challengeRole of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.MsbA transporter-dependent lipid A 1-dephosphorylation on the periplasmic surface of the inner membrane: topography of francisella novicida LpxE expressed in Escherichia coliExpression cloning and biochemical characterization of a Rhizobium leguminosarum lipid A 1-phosphataseCharacterization of the O-4 phosphorylated and O-5 substituted Kdo reducing end group and sequencing of the core oligosaccharide of Aeromonas salmonicida ssp salmonicida lipopolysaccharide using tandem mass spectrometry.Expression cloning and periplasmic orientation of the Francisella novicida lipid A 4'-phosphatase LpxF.Shield as signal: lipopolysaccharides and the evolution of immunity to gram-negative bacteria.Glucosamine found as a substituent of both phosphate groups in Bordetella lipid A backbones: role of a BvgAS-activated ArnT orthologSynthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model.Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriersSynthesis of serine-based glycolipids as potential TLR4 activators.Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.Utilizing the O-antigen lipopolysaccharide biosynthesis pathway in Escherichia coli to interrogate the substrate specificities of exogenous glycosyltransferase genes in a combinatorial approachKdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4.Modifications of glycans: biological significance and therapeutic opportunitiesBacterial cell surface structures in Yersinia enterocolitica.TLR-based immune adjuvants.Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restriAdministration of a synthetic TLR4 agonist protects mice from pneumonic tularemia.Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptorsKdo2 -lipid A: structural diversity and impact on immunopharmacology.In vitro and in vivo anticancer activity of a synthetic glycolipid as Toll-like receptor 4 (TLR4) activator.Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 miceCarbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouseCan innate immunity be enhanced to treat microbial infections?Stimulation of T-helper cell gamma interferon and immunoglobulin G responses specific for Babesia bovis rhoptry-associated protein 1 (RAP-1) or a RAP-1 protein lacking the carboxy-terminal repeat region is insufficient to provide protective immunityGene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant.Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cellsDiscovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.
P2860
Q24645758-034F29EF-4009-42BB-A1A8-30092FBE50DDQ24650951-7AC4C292-2396-457D-AC3B-F5255C2989F0Q26740513-A3E230A5-4FF3-463C-9B44-C82DA222A9C2Q26748776-7C44B679-B1B4-4151-BC23-6AB7169C1F58Q26780331-076B95B2-988C-48B3-BD41-94CE44AAB671Q26992220-BBA92ABA-4BDE-4FF6-B0BB-67C8CBC30189Q27008380-C0F80259-EAC2-4A0C-B475-FB72DD743393Q28256294-676EC42F-A343-4ED1-9723-343F23FA4924Q30157760-DC53A0D3-A821-4EFD-B10B-BDF035403CC3Q30354064-DF93DDA2-E6D0-4B9C-9286-37862894194DQ30424747-4BA63085-02BD-4845-9484-31EAD81B2504Q30840136-A7067358-0881-4A22-B744-333AE272C964Q30965642-710DE4A7-55E9-474C-B030-2C8C1D24E628Q33208794-DC2A02B8-0D2D-4A94-AA6F-7E170A1A1D46Q33233454-48A424BC-EAC8-4FB7-B775-E1EE77747E97Q33250412-B4678FE6-78B1-4C63-9896-D27C90B1BC21Q33329463-37BEE14C-4102-471A-AAD8-864C0EE2A041Q33768989-2A0CCCF5-3364-4556-9340-4E490B7CDA17Q33795071-A97EDC40-F155-4525-8004-646F65534D0BQ33819711-4C05E9A6-30CB-49CB-9D81-B2E2A565E503Q33825150-26C7630C-37B2-499B-953E-BE06349FB908Q33956199-73F3F885-A46C-4008-8813-3B9F5946F10CQ33979011-24E8EF60-15EA-45CD-8C85-2B7BABD77E9FQ33993559-15357772-ECF8-4E3E-AE65-1DCB15B8121CQ34111293-3A078D93-A28C-4398-96C0-1E5310F3EC2AQ34266677-01FEEA43-566F-4E59-91A0-E1347133843DQ34400322-1B4130BE-A817-4519-8995-E79B42479844Q34439215-77FC7343-9A85-4D2C-8AB3-A444FEFE2EE7Q34714290-267F085B-7E37-4F95-92CF-2FC0CA0C2D16Q35220354-05C95386-7616-4CFC-9A52-934026EAA291Q35468441-39C8E1D6-7DE5-4715-90C1-8AB0A43E00BBQ35626184-D91535DD-2FA4-4720-87D8-9CD11188E5D7Q35634197-1897EC38-BC19-4485-9F7E-4668E27CD652Q35685656-F0F88AC8-5C0D-4C7D-AA8C-5DCA7BEDCBFEQ35777677-AE9B66B5-6806-492D-937F-2EC164A184DDQ35802276-C48F1C4C-8342-4E6D-A5DA-0BECA764903DQ35886513-A0E10184-5A90-44BF-9CCA-BD7A82BE6871Q35946895-FD621DCA-85EA-441F-B449-045543E67922Q35947234-6C8C7DB5-743D-48B4-995D-D4BEE391FDA5Q35981265-EB62B411-5374-4763-B042-8F654845D9AD
P2860
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
@ast
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
@en
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
@nl
type
label
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
@ast
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
@en
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
@nl
prefLabel
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
@ast
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
@en
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
@nl
P2093
P1476
Taking toll: lipid A mimetics as adjuvants and immunomodulators.
@en
P2093
David A Johnson
David H Persing
Jory R Baldridge
Michael J Lacy
Rhea N Coler
Robert M Hershberg
P356
10.1016/S0966-842X(02)02426-5
P433
P577
2002-01-01T00:00:00Z